Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Cdiff Test to detect Clostridium difficile (C. difficile) ...
Roche ($RHHBY) got an FDA OK for its rapid test for Clostridium difficile, picking up another regulatory gold star as it broadens its offerings on its cobas 4800 ...
This is a preview. Log in through your library . Abstract Background. Clostridium difficile-associated diarrhea (CDAD) is the major cause of health care-associated infectious diarrhea. Current ...
The U.S. Food and Drug Administration has granted 510(k) clearance for Roche’s test for C.difficile. Its Cobas Test targets the toxin B gene found in toxigenic C. difficile strains in stool samples ...
Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...
C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most common causes of diarrhea linked to ...
Patients with Clostridioides difficile infection had different bacterial and fungal composition in their stool compared with that of uninfected patients, researchers found. Distinct species of fungus ...
C. diff is a type of bacteria that can cause diarrhea, abdominal pain, and tenderness. It is commonly treated with antibiotics such as fidaxomicin (Dificid) and vancomycin (Firvanq). C. diff, short ...
The U.S. Food and Drug Administration issued a warning Thursday following the death of a patient who received a fecal transplant containing drug-resistant bacteria. Fecal transplants are used to treat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results